Intelligence · Clinical Development
Pipeline search results
Programs matching “prostate-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 133 pipeline programs matching "prostate-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Dupilumab
Regeneron UK Limited
Prostate Cancer
1 trial -
Enzalutamide
BRIGHT MINDS BIOSCIENCES INC.
Prostate Cancer Metastatic
1 trial -
Enzalutamide 40mg
United Therapeutics Europe Ltd
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
Exicorilant
CORCEPT THERAPEUTICS INC
Metastatic Castration-Resistant Prostate Cancer
1 trial -
FirstHCMU-JBi-PARTOM
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Castrate-Resistant Prostate Cancer
1 trial -
Immunomodulatory DC vaccines to target prostate cancer
Shenzhen Second People's Hospital
Prostate Cancer Indications
1 trial -
Irofulven
Allarity Therapeutics
Metastatic Castration-Resistant Prostate Cancer Patients
1 trial -
NRX 194204
IO Biotech
Castration Resistant Prostate Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Prostate Cancer
1 trial -
OGX-011
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
Onvansertib
Cardiff Oncology
Metastatic Castration-Resistant Prostate Cancer
1 trial -
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Telix Innovations
Prostate Cancer
1 trial -
Panzem® NCD
CASI Pharmaceuticals
Prostate Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Castration-resistant Prostate Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Prostate alone IMRT
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
Quemliclustat
Arcus Biosciences
Oligometastatic Prostate Cancer
1 trial -
REGN15505
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
REGN2810
Regeneron UK Limited
Prostate Cancer Metastatic
1 trial -
REGN4336
Regeneron UK Limited
Metastatic Castration-resistant Prostate Cancer
1 trial -
REGN5678
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
Relugolix
Takeda
Prostate Cancer
1 trial -
Rezvilutamide
Nanjing Zenshine Pharmaceuticals
Prostate Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.